About the Master

Xin Xianliang is Director of the GV-971 R&D Project at Green Valley Research Institute, as well as one of the key inventors of GV-971.

About the e-Class

According to the results of the 36-week China phase-3 clinical study, GV-971 demonstrated significant efficacy in improving cognition with sustained improvement across the observation period, while being safe. That indicates GV-971 is an AD drug with potentials in improving patients’ cognitive function, alleviating the symptoms, and delaying the disease progression over the long term.